{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:45:34Z","timestamp":1788637534200,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Failures to treat triple-negative breast cancer (TNBC) are mainly due to chemoresistance or radioresistance. We and others previously discovered that zinc finger E-box-binding homeobox 1 (ZEB1) is a massive driver causing these resistance. However, how to dynamically modulate the intrinsic expression of ZEB1 during cell cycle progression is elusive. Here integrated affinity purification combined with mass spectrometry and TCGA analysis identify a cell cycle-related E3 ubiquitin ligase, checkpoint with forkhead and ring finger domains (CHFR), as a key negative regulator of ZEB1 in TNBC. Functional studies reveal that CHFR associates with and decreases ZEB1 expression in a ubiquitinating-dependent manner and that CHFR represses fatty acid synthase (FASN) expression through ZEB1, leading to significant cell death of TNBC under chemotherapy. Intriguingly, a small-molecule inhibitor of HDAC under clinical trial, Trichostatin A (TSA), increases the expression of CHFR independent of histone acetylation, thereby destabilizes ZEB1 and sensitizes the resistant TNBC cells to conventional chemotherapy. In patients with basal-like breast cancers, CHFR levels significantly correlates with survival. These findings suggest the therapeutic potential for targeting CHFR-ZEB1 signaling in resistant malignant breast cancers.<\/jats:p>","DOI":"10.1038\/s41419-021-04114-8","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:03:09Z","timestamp":1630324989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CHFR regulates chemoresistance in triple-negative breast cancer through destabilizing ZEB1"],"prefix":"10.1038","volume":"12","author":[{"given":"Hong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-5035","authenticated-orcid":false,"given":"Yuan","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-8710","authenticated-orcid":false,"given":"Peijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"4114_CR1","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"key":"4114_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl J Med. 2010;363:1938\u201348. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N. Engl J Med"},{"key":"4114_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738507666190122111224","volume":"7","author":"FA Fisusi","year":"2019","unstructured":"Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanotechnol. 2019;7:3\u201323. https:\/\/doi.org\/10.2174\/2211738507666190122111224","journal-title":"Pharm Nanotechnol"},{"key":"4114_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","volume":"154","author":"CL Chaffer","year":"2013","unstructured":"Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154:61\u201374. https:\/\/doi.org\/10.1016\/j.cell.2013.06.005","journal-title":"Cell"},{"key":"4114_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/ncb3513","volume":"19","author":"AM Krebs","year":"2017","unstructured":"Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19:518\u201329. https:\/\/doi.org\/10.1038\/ncb3513","journal-title":"Nat Cell Biol"},{"key":"4114_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/ncb3050","volume":"16","author":"Y Wang","year":"2014","unstructured":"Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1. Nat Cell Biol. 2014;16:1092\u2013104. https:\/\/doi.org\/10.1038\/ncb3050","journal-title":"Nat Cell Biol"},{"key":"4114_CR7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1091\/mbc.E11-02-0103","volume":"22","author":"PA Gregory","year":"2011","unstructured":"Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta\/ZEB\/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22:1686\u201398. https:\/\/doi.org\/10.1091\/mbc.E11-02-0103","journal-title":"Mol Biol Cell"},{"key":"4114_CR8","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/sj.onc.1208429","volume":"24","author":"A Eger","year":"2005","unstructured":"Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005;24:2375\u201385. https:\/\/doi.org\/10.1038\/sj.onc.1208429","journal-title":"Oncogene"},{"key":"4114_CR9","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487\u201395. https:\/\/doi.org\/10.1038\/ncb1998","journal-title":"Nat Cell Biol"},{"key":"4114_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/15384101.2015.1006048","volume":"14","author":"P Zhang","year":"2015","unstructured":"Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14:481\u20137. https:\/\/doi.org\/10.1080\/15384101.2015.1006048","journal-title":"Cell Cycle"},{"key":"4114_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0087-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Zhang Z, Zhang Q, Zhang Q, Sun P, Xiang R, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018;9:57 https:\/\/doi.org\/10.1038\/s41419-017-0087-3","journal-title":"Cell Death Dis"},{"key":"4114_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/ncb3013","volume":"16","author":"P Zhang","year":"2014","unstructured":"Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16:864\u201375. https:\/\/doi.org\/10.1038\/ncb3013","journal-title":"Nat Cell Biol"},{"key":"4114_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6671","volume":"5","author":"P Zhang","year":"2014","unstructured":"Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, et al. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014;5:5671 https:\/\/doi.org\/10.1038\/ncomms6671","journal-title":"Nat Commun"},{"key":"4114_CR14","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/mt.2014.79","volume":"22","author":"MA Cortez","year":"2014","unstructured":"Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22:1494\u2013503. https:\/\/doi.org\/10.1038\/mt.2014.79","journal-title":"Mol Ther"},{"key":"4114_CR15","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1073\/pnas.1337066100","volume":"100","author":"M Toyota","year":"2003","unstructured":"Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA. 2003;100:7818\u201323. https:\/\/doi.org\/10.1073\/pnas.1337066100","journal-title":"Proc Natl Acad Sci USA"},{"key":"4114_CR16","first-page":"8606","volume":"63","author":"A Satoh","year":"2003","unstructured":"Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 2003;63:8606\u201313.","journal-title":"Cancer Res"},{"key":"4114_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10555-013-9462-4","volume":"33","author":"S Derks","year":"2014","unstructured":"Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, et al. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 2014;33:161\u201371. https:\/\/doi.org\/10.1007\/s10555-013-9462-4","journal-title":"Cancer Metastasis Rev"},{"key":"4114_CR18","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/onc.2009.123","volume":"28","author":"L Kashima","year":"2009","unstructured":"Kashima L, Toyota M, Mita H, Suzuki H, Idogawa M, Ogi K, et al. CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB. Oncogene. 2009;28:2643\u201353. https:\/\/doi.org\/10.1038\/onc.2009.123","journal-title":"Oncogene"},{"key":"4114_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ncb1837","volume":"11","author":"YM Oh","year":"2009","unstructured":"Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo SJ, et al. Chfr is linked to tumour metastasis through the downregulation of HDAC1. Nat Cell Biol. 2009;11:295\u2013302. https:\/\/doi.org\/10.1038\/ncb1837","journal-title":"Nat Cell Biol"},{"key":"4114_CR20","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1128\/mcb.19.12.8581","volume":"19","author":"T Furusawa","year":"1999","unstructured":"Furusawa T, Moribe H, Kondoh H, Higashi Y. Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1. Mol Cell Biol. 1999;19:8581\u201390. https:\/\/doi.org\/10.1128\/mcb.19.12.8581","journal-title":"Mol Cell Biol"},{"key":"4114_CR21","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1073\/pnas.96.12.6683","volume":"96","author":"AA Postigo","year":"1999","unstructured":"Postigo AA, Dean DC. ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci USA. 1999;96:6683\u20138. https:\/\/doi.org\/10.1073\/pnas.96.12.6683","journal-title":"Proc Natl Acad Sci USA"},{"key":"4114_CR22","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1038\/onc.2011.612","volume":"31","author":"V Byles","year":"2012","unstructured":"Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31:4619\u201329. https:\/\/doi.org\/10.1038\/onc.2011.612","journal-title":"Oncogene"},{"key":"4114_CR23","first-page":"2020","volume":"7","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Zhang P, Hu X, Kim J, Yao F, Xiao Z, et al. USP51 promotes deubiquitination and stabilization of ZEB1. Am J Cancer Res. 2017;7:2020\u201331.","journal-title":"Am J Cancer Res"},{"key":"4114_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1083\/jcb.200108016","volume":"156","author":"D Kang","year":"2002","unstructured":"Kang D, Chen J, Wong J, Fang G. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002;156:249\u201359. https:\/\/doi.org\/10.1083\/jcb.200108016","journal-title":"J Cell Biol"},{"key":"4114_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng1538","volume":"37","author":"X Yu","year":"2005","unstructured":"Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet. 2005;37:401\u20136. https:\/\/doi.org\/10.1038\/ng1538","journal-title":"Nat Genet"},{"key":"4114_CR26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nsmb.2078","volume":"18","author":"J Wu","year":"2011","unstructured":"Wu J, Chen Y, Lu LY, Wu Y, Paulsen MT, Ljungman M, et al. Chfr and RNF8 synergistically regulate ATM activation. Nat Struct Mol Biol. 2011;18:761\u20138. https:\/\/doi.org\/10.1038\/nsmb.2078","journal-title":"Nat Struct Mol Biol"},{"key":"4114_CR27","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/nar\/gks1278","volume":"41","author":"C Liu","year":"2013","unstructured":"Liu C, Wu J, Paudyal SC, You Z, Yu X. CHFR is important for the first wave of ubiquitination at DNA damage sites. Nucleic Acids Res. 2013;41:1698\u2013710. https:\/\/doi.org\/10.1093\/nar\/gks1278","journal-title":"Nucleic Acids Res"},{"key":"4114_CR28","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.7150\/thno.45037","volume":"10","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020;10:7974\u201392. https:\/\/doi.org\/10.7150\/thno.45037","journal-title":"Theranostics"},{"key":"4114_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrc2222","volume":"7","author":"JA Menendez","year":"2007","unstructured":"Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763\u201377. https:\/\/doi.org\/10.1038\/nrc2222","journal-title":"Nat Rev Cancer"},{"key":"4114_CR30","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-15-3133","volume":"22","author":"A Gir\u00f3-Perafita","year":"2016","unstructured":"Gir\u00f3-Perafita A, Palomeras S, Lum DH, Blancafort A, Vi\u00f1as G, Oliveras G, et al. Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer. Clin Cancer Res. 2016;22:4687\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3133","journal-title":"Clin Cancer Res"},{"key":"4114_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/B:BREA.0000018409.59448.60","volume":"84","author":"JA Menendez","year":"2004","unstructured":"Menendez JA, Lupu R, Colomer R. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2\/neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat. 2004;84:183\u201395. https:\/\/doi.org\/10.1023\/B:BREA.0000018409.59448.60","journal-title":"Breast Cancer Res Treat"},{"key":"4114_CR32","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1073\/pnas.182372299","volume":"99","author":"LM Butler","year":"2002","unstructured":"Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA. 2002;99:11700\u20135. https:\/\/doi.org\/10.1073\/pnas.182372299","journal-title":"Proc Natl Acad Sci USA"},{"key":"4114_CR33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm.3327","volume":"19","author":"T Brabletz","year":"2013","unstructured":"Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nat Med. 2013;19:1104\u20139. https:\/\/doi.org\/10.1038\/nm.3327","journal-title":"Nat Med"},{"key":"4114_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gy\u00f6rffy","year":"2010","unstructured":"Gy\u00f6rffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725\u201331. https:\/\/doi.org\/10.1007\/s10549-009-0674-9","journal-title":"Breast Cancer Res Treat"},{"key":"4114_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177","journal-title":"Cancer Discov"},{"key":"4114_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"4114_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/stem.3301","volume":"39","author":"S Ehmsen","year":"2021","unstructured":"Ehmsen S, Ditzel HJ. Signaling pathways essential for triple-negative breast cancer stem-like cells. Stem Cells. 2021;39:133\u201343. https:\/\/doi.org\/10.1002\/stem.3301","journal-title":"Stem Cells"},{"key":"4114_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19:39\u201356. https:\/\/doi.org\/10.1038\/s41573-019-0044-1","journal-title":"Nat Rev Drug Discov"},{"key":"4114_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.stem.2018.11.011","volume":"24","author":"PB Gupta","year":"2019","unstructured":"Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell. 2019;24:65\u201378. https:\/\/doi.org\/10.1016\/j.stem.2018.11.011","journal-title":"Cell Stem Cell"},{"key":"4114_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19:377\u201391. https:\/\/doi.org\/10.1038\/s41568-019-0154-4","journal-title":"Nat Rev Cancer"},{"key":"4114_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fmolb.2020.00036","volume":"7","author":"S Drapela","year":"2020","unstructured":"Drapela S, Bouchal J, Jolly MK, Culig Z, Soucek K. ZEB1: a critical regulator of cell plasticity, DNA damage response, and therapy resistance. Front Mol Biosci. 2020;7:36 https:\/\/doi.org\/10.3389\/fmolb.2020.00036","journal-title":"Front Mol Biosci"},{"key":"4114_CR42","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.4161\/cc.7.20.6851","volume":"7","author":"PA Gregory","year":"2008","unstructured":"Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008;7:3112\u20138. https:\/\/doi.org\/10.4161\/cc.7.20.6851","journal-title":"Cell Cycle"},{"key":"4114_CR43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.4149\/neo_2018_181212N476","volume":"65","author":"X Song","year":"2018","unstructured":"Song X, Wu JQ, Yu XF, Yang XS, Yang Y. Trichostatin A inhibits proliferation of triple negative breast cancer cells by inducing cell cycle arrest and apoptosis. Neoplasma. 2018;65:898\u2013906. https:\/\/doi.org\/10.4149\/neo_2018_181212N476","journal-title":"Neoplasma"},{"key":"4114_CR44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.celrep.2018.03.078","volume":"23","author":"P Zhang","year":"2018","unstructured":"Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, et al. ZRANB1 is an EZH2 deubiquitinase and a potential therapeutic target in breast cancer. Cell Rep. 2018;23:823\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.078","journal-title":"Cell Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04114-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:20:41Z","timestamp":1669972841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04114-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["4114"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04114-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper dose not describe studies involving human participants, human data, or human tissue. All animal experiments were approved by the Ethics Committee of Tongji Medical College, Huangzhong University of Science and Technology, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"820"}}